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Acupuncture in Patients Suffering from Allergic Asthma:
Is It Worth Additional Costs?
Thomas Reinhold, PhD, Benno Brinkhaus, MD, Stefan N. Willich, MD, and Claudia Witt, MD
Abstract
Objectives: Acupuncture is increasingly used in patients with allergic asthma, but there is a lack of evidence on
the cost–benefit relationship of this treatment. The aim of this study was to assess economic aspects of additional
acupuncture treatment in patients with allergic bronchial asthma compared to patients receiving routine care
alone.
Design, subjects, intervention, outcome measures: In a randomized controlled trial, patients with allergic
bronchial asthma were either allocated to a group receiving acupuncture immediately or a waiting-list control
group. Both groups were free to use routine care treatment. The resource consumption, costs, and health-related
quality of life were evaluated at baseline, and after 3 and 6 months by using statutory health insurance infor-
mation and standardized questionnaires. Main economic outcome parameters were direct and indirect cost
differences during the study period and the incremental cost-effectiveness ratio (ICER) of acupuncture treatment.
Results: Three hundred and six (306) patients (159 acupuncture; 147 controls) were included (mean age
46.5 – 13.11 years, female 57.2%) and were comparable at baseline. Acupuncture treatment was associated with
significantly higher costs compared to control patients (overall costs: e860.76 [95% confidence interval (CI)
705.04–1016.47] versus e518.80 [95% CI 356.66–680.93]; p = 0.003; asthma-related costs: e517.52 [95% CI 485.63–
549.40] versus e144.87 [95% CI 111.70–178.05]; p < 0.001). These additional costs seem essentially driven by
acupuncture costs themselves (e378.40 [95% CI 367.10–389.69]). However, acupuncture was associated with
superior effectiveness in terms of quality-adjusted life years (QALYs). Resulting ICER lay between e23,231
(overall) and e25,315 (diagnosis-specific) per additional QALY. When using German acupuncture prices of year
2012, the ICER would improve to e12.810 (overall) versus e14,911 (diagnosis-specific) per QALY gained.
Conclusions: Treating patients who have allergic bronchial asthma with acupuncture in addition to routine care
resulted in additional costs and better effects in terms of patients’ quality of life. Acupuncture therefore seems to
be a useful and cost-effective add-on treatment.
Introduction
Asthma is one of the most common chronic disordersin developed countries.1 The prevalence varies from
country to country and has been estimated to be 7% in
France and Germany up to 11% in the United States and
15%–18% in the United Kingdom.2 Worldwide the literature
indicates that about 300 million people are suffering from
this disorder.3
Often asthma is not well controlled and is associated with
additional restrictions in daily life as well as the resulting
quality of life.3,4 The disease starts in childhood and is highly
prevalent up to old age. The current studies indicate that
most asthma cases are due to allergic conditions. Studies
indicate that 90% of all asthma patients had symptoms cor-
related with allergic rhinitis and 38% of rhinitis patients also
had asthmatic symptoms.5
Beside this, asthma is associated with a remarkable eco-
nomic burden, while hospitalization and medications were
found to be the most important cost drivers of direct costs;
the indirect costs were mainly driven by work and school
loss.6 In Germany, the annual patient-related direct and in-
direct costs range between e2202 for children and e7745 for
adults with moderate asthma, and between e7928 and
e9,286, respectively, for children and adults with severe
asthma (year 2000).7 In 2008, the Federal Statistical Office
calculated total direct costs of about e1.8 billion for Ger-
many.8 Assuming that the proportion of indirect costs on
total amount of disease burden is given as 45%,9 the total
asthma costs in 2008 can be estimated to be e3.3 billion.
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Despite advances in pharmacotherapy, complementary
and alternative medicine is widely used by patients suffering
from allergic disorders. A German study found that about
26.5% of patients received such therapies because of their
allergy.10 This fact supports the economic evaluation of
nonpharmacological treatment options, such as acupuncture.
In Germany, acupuncture is mainly administered by physi-
cians. The treatment is a relatively resource-intensive inter-
vention due to the time involved for physicians and patients
alike.11 To date, there is a lack of information on costs
and cost–benefit relationship of acupuncture compared to
routine-care treatment.
Objective
The main objective of the present health-economic analysis
was to compare effectiveness and costs of an additional
acupuncture treatment in patients with bronchial asthma
compared to routine care alone.
Methods
Study design and patients
In this pragmatic12 multicenter, randomized, controlled
trial, patients (‡ 18 years of age) with a clinical diagnosis of
allergic bronchial asthma (ICD-codes: J44.8, J44.9, J45.0; J45.1,
J45.8, J45.9, J46) were enrolled after contacting the partici-
pating physician until 2001. Allergic asthma was defined as
an inflammatory disease of the airways with bronchial hy-
peractivity and variable airway obstruction, often associated
with an atopic predisposition. Other respiratory diseases or
expiratory dyspnea, as well as the suspicion of bronchial
asthma with nonallergic origin, were exclusion criteria.
The diagnosis of asthma was conducted as always done in
the health insurance system, and the tests used have been
documented by the participating doctors. After giving their
informed consent, patients were randomly allocated to an
acupuncture group that received immediate acupuncture
treatment over a period of 3 months after study or to a
waiting-list control group that received delayed acupuncture
treatment between months 3 to 6. Patients in both groups
were free to use conventional routine medical care as usually
compensated by the German statutory health insurance
companies.
Participating physicians were required to have received at
least 140 hours of acupuncture training. The number, length,
and diameter of the needles and the selection of acupuncture
points were decided on by the participating doctors them-
selves and for each patient individually. The acupuncture
treatments consisted of 10–15 acupuncture sessions during
the study period.
The study project was approved by the Ethics committee
of Charite´–University Medical Center Berlin/Germany (No.
1424/2000). Further detailed information on the study pro-
ject (trial registration number DRKS00003767) were already
published elsewhere.13
Resource consumption and cost measurement
The costs were determined bottom-up, by monetary val-
uation of a patient’s resource consumption during the period
of 3 months after randomization. Information on the re-
source use was obtained by using statutory health insurance
databases provided by ‘‘Techniker Krankenkasse’’ (Techni-
cians’ Health Insurance Comp.). Costs considered were di-
rect health care such as costs physicians’ visits, hospital stays
(without consideration of private individual billing) as well
as prescription drugs (including patient’s co-payment) and
the costs of acupuncture sessions itself. In our study, e35
were paid for each acupuncture session (base-case). To also
reflect the current cost-effectiveness of acupuncture, 2012
acupuncture prices of e21 per session were used in a sensi-
tivity analysis.
The cost perspective of the study was societal. Therefore,
in addition to health insurance costs we also considered in-
direct costs caused by patients’ work incapacity. These in-
direct costs were determined by using the human capital
approach14 and were estimated to be about e78 per day sick
away from work.
During the first 3 months of direct comparison, the fol-
lowing were calculated: (1) diagnosis-specific costs using
ICD-10 codes to identify costs due to only allergic bronchial
asthma and related conditions and (2) the overall costs after
randomization, including costs not related to allergic asthma.
Outcome measurement and quality-adjusted life year
determination
Effectiveness was evaluated using quality-of-life data
determined with the 36-Item Short Form Health Survey
(SF-36).15 This questionnaire consists of 36 questions, is self-
administered, and assesses quality of life and well-being in 8
subscales regarding physical functioning and perception of
physical role, vitality, general and mental health, perception
of emotional role, social functioning, and bodily pain. Patients
were asked to complete this questionnaire at baseline, and
after 3 months and 6 months. These SF-36 quality-of-life-data
were converted to health-state utilities using an algorithm
developed by Brazier et al.16 As a result, such health-state
utilities were obtained for the time points: baseline, 3
months, as well as 6 months after study onset. Between these
time points, the common assumption of a linear change of
health-state utilities over time was used.17
Since the control group did also receive acupuncture after
their waiting time of 3 months, it was not possible to perform
a direct group comparison during months 3 and 6. Other-
wise, if the comparison would only be restricted to the first 3
months of the study, it would not be disclosed that acu-
puncture patients might experience further acupuncture ef-
fects on their quality of life. In order to achieve a longer
comparison period, it was assumed that control patients
would not get acupuncture between months 3 and 6.
Therefore, a further assumption was that the utility-trend in
control patients during the time would be the same as was
observed in the acupuncture patients. Based on this, a new
utility for time point 6 months after baseline was modeled for
control patients. The utilities in acupuncture were taken as
reported. After that, the resulting quality-adjusted life years
(QALYs) were calculated by adopting the area-under-the-
curve method.17,18
Cost-effectiveness assessment
Cost-effectiveness analysis was calculated for all ran-
domized patients with complete data on costs and effects.
Since the intervention effects were considered in terms of
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quality of life, the cost-effectiveness measurement was per-
formed as a cost-utility analysis. In case of superior quality of
life compared to control patients, the cost-effectiveness of
acupuncture was calculated as the relation between group
differences in costs and differences in QALYs, the so-called
incremental cost-effectiveness ratio (ICER):
ICER¼ mean costsacupuncture mean costscontrols
mean QALYsacupuncture mean QALYscontrols
The ICER reflects the additional costs associated with re-
alizing 1 additional QALY compared to the control patients.
In health economic studies, particularly in Western Europe, a
threshold l up to e50,000 per QALY gained is often used to
decide whether an intervention is cost-effective or not.19 A
health technology can be seen as a cost-effective intervention
(in terms of value for money), if the realization of one ad-
ditional QALY is reachable with less than e50,000. Thus, the
threshold l is often described as society’s willingness to pay
for 1 extra QALY. This threshold was also used in order to
reach a better comparability of international study results,
knowing well that such a threshold does not yet exist in
German health care decision-making.
Additionally, the net benefit approach20 was used to
measure the incremental cost-effectiveness against different
societal threshold values l. For a given threshold value l, an
intervention would be considered to be cost-effective if its
net benefit is greater than zero.21 The net benefit is defined
by the following relation:
Net benefit¼ (k QALYsgained for acupuncture)
(mean costsacupuncture mean costscontrol)
To derive cost-effectiveness acceptability curves, non-
parametric bootstrapping was used.22 When using the
bootstrap approach, repeated random samples of the same
size as the original population are drawn with replacement
from the data. In this study’s analysis, the original sample
was bootstrapped 1000 times to obtain 1000 means for cost
and effect differences and the resulting ICERs. These boot-
strapped results were transformed into net benefit values
under varying threshold values and then plotted in a cost-
effectiveness acceptability curve. The cost-effectiveness ac-
ceptability curve shows the probability that an intervention
is cost-effective against different values of l.21 For example:
For each of the 1000 bootstrapped cost- and effect-differ-
ences, the net benefit was calculated against assumed values,
reflecting society’s willingness to pay for an additional
QALY (e.g., l= e20,000). In the case that 250 of the resulting
1000 net-benefit results were larger than zero, it was con-
cluded that the probability of cost-effectiveness was 25%.
Additionally, the bootstrap samples were used to get a
graphical overview on the distribution of incremental cost-
effectiveness ratios.
Statistical analyses
Socioeconomic data at baseline were analyzed by using
Student’s t-test for comparing continuous variables (e.g.,
patient’s age, disease duration) and v2 test for dichotomous
variables (e.g., gender). Baseline costs in both groups were
analyzed using Mann–Whitney U test. Furthermore, analysis
of covariance was applied for estimation and comparison of
adjusted cost and effectiveness values for months 3 and 6.
Adjusting variables were age, gender, education, duration of
disease, number of comorbidities, AQLQ-Score (Asthma
Quality of Life Questionnaire) at baseline, health-state utility
at baseline and the respective baseline value. To derive cost-
effectiveness acceptability curves, nonparametric boot-
strapping were used, as described above.
The significance level was 5% (two-sided). For inferential
statistics, we used SPSSª version 11.0. Finally, we used MS
Excelª 2003 to model bootstrapped cost-effectiveness ana-
lyses.
Results
Baseline characteristics
A total of 357 patients suffering from allergic asthma
were randomized after initial contact with the participating
physicians. Three hundred and six (306) of them (159 acu-
puncture; 147 controls) with complete dataset could be
analyzed within the economic analyses (Fig. 1). Participat-
ing patients had a mean age of 46.5 – 13.11 years and were
mostly female (57.2%). With regard to socioeconomic vari-
ables at baseline, there were no relevant group-differences
detectable and also patient’s quality of life, reflected by
AQLQ-Score (restricted to asthma-related quality of life) as
well as Health-state utilities, seems comparable in both
groups (Table 1).
Resource consumption and costs
The patient groups were comparable in terms of their re-
source consumption prior to the study, with the exception of
asthma-related outpatient contacts. As documented in Table
1, patients allocated to the acupuncture group experienced
more physician visits than patients of the control group
(1.63 – 5.59 visits versus 0.82 – 3.17 visits; p = 0.040). This
difference is also reflected in outpatient costs related to
asthma (23.01 – 87.53 Euro versus 11.47– 44.82 Euro;
p= 0.041). Compared to controls, the total overall costs of
patients assigned to the acupuncture group were found to be
slightly higher at baseline (e636.01– e1180.52 Euro versus
e526.92– e1341.08 Euro; p = 0.035).
During the study, the acupuncture patients received a
mean number of 10.8 (95% CI 10.4–11.3) acupuncture ses-
sions (Table 2). However, this additional intervention did not
lead to a substantial reduction of consumed resources and
following costs in other health care areas. The mean overall
costs of acupuncture patients during the study period were
significant higher than for controls (overall: e860.76; 95% CI
e705.04–e1016.47) versus e518.80 (95% CI e356.66–e680.93);
p= 0.003, asthma-related: e517.52 (95% CI e485.63–e549.40)
versus e144.87 (95% CI e111.70–e178.05); p< 0.001). The
mean cost difference between both treatment groups (over-
all: e341.96; 95% CI e115.88–e568.04; asthma-related:
e372.65; 95% CI e326.36–e418.93) seems essentially driven by
the acupuncture costs itself (e378.40; 95% CI e367.10–
e389.69). After excluding acupuncture session costs we
found no longer a significant difference in costs between
both treatment arms (overall: e477.17; 95% CI e321.35–
e633.00) versus e518.80; 95% CI e356.66–e680.93; p = 0.718
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Table 1. Baseline Patient’s Characteristics, Resource Consumption and Costs
During 3Months Before Study Onset
Acupuncture (n = 159) Control (n= 147) p-Value
Sociodemographic characteristics (in % [n] resp. mean– SD)
Proportion of female patients 59.1% (94) 55.1% (81) 0.490
Patients age (years) 46.78– 12.41 46.31– 13.86 0.751
Patients > 10 years of school 44.0% (70) 49.0% (72) 0.423
Disease duration (years) 14.32– 12.84 12.6 – 11.64 0.229
Mean number of comorbidities 0.59 – 1.08 0.54 – 0.97 0.646
AQLQ score 4.37 – 1.12 4.47 – 0.93 0.425
Health-state utility 0.6979– 0.1239 0.7191– 0.1107 0.116
Asthma-related quantity of resource consumption (mean number – SD)
Outpatient visits 1.63 – 5.59 0.82 – 3.17 0.040
Drug-prescriptions 2.03 – 2.47 1.84 – 2.32 0.740
Hospital days 0.06 – 0.79 — 0.336
Days of work incapacity 0.30 – 1.60 0.14 – 1.29 0.190
Asthma-related costs in euros (mean costs per patient – SD)
Outpatient visits 23.01– 87.53 11.47– 44.82 0.041
Medication 89.97– 123.19 87.00– 148.00 0.715
Hospital stays 11.71– 147.66 — 0.336
Indirect costs 23.59– 125.17 20.20– 163.09 0.378
Total asthma-related costs 148.29– 264.94 118.66– 231.57 0.096
Overall quantity of resource consumption (mean number – SD)
Outpatient visits 2.40 – 5.82 2.04 – 4.53 0.306
Drug prescriptions 5.38 – 5.51 4.31 – 4.62 0.132
Hospital days 0.67 – 2.80 0.30 – 1.90 0.077
Days of work incapacity 2.76 – 7.69 1.81 – 5.08 0.078
Overall costs in euros (mean costs per patient – SD)
Outpatient visits 33.37– 90.01 27.72– 61.97 0.318
Medication 178.65– 272.27 155.97– 286.60 0.242
Hospital stays 198.14– 875.27 88.25– 595.18 0.077
Indirect costs 225.85– 697.31 254.98– 961.01 0.124
Total overall costs 636.01– 1180.52 526.92– 1341.08 0.035
AQLQ, Asthma Quality of Life Questionnaire; resp., respectively.
FIG. 1. Study flowchart.
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(asthma-related: e134.22; 95% CI e105.31–e163.13) versus
e144.87 (95% CI e111.70–e178.05); p= 0.631).
Effectiveness
During the first 3 months of the study, the patients re-
ceiving acupuncture experienced a considerable improve-
ment (Fig. 2). The mean health state utilities increased from
0.6979 (95% CI 0.6786–0.7173) at baseline to 0.7623 (95% CI
0.7468–0.7778) 3 months after. However, although no further
acupuncture sessions were offered to these patients after the
first 3 months of the study, further improvements in quality
of life were observed between months 3 and 6. The utility 6
months after study onset increased to 0.7754 (95% CI 0.7591–
0.7918). In contrast, patients allocated to the control group
showed no changes in their quality of life assessment during
the first 3 months of the study. Between months 3 and 6, these
patients were also able to receive acupuncture. As a result, a
comparable quality-of-life improvement as observed in acu-
puncture patients during the first 3 months was detectable.
According to the previous assumption that control pa-
tients would not get acupuncture between months 3 and 6,
the resulting QALYs for that group were 0.3592 (95% CI
0.3534–0.3650). That is significant less ( p< 0.001) compared
to acupuncture patients who experienced mean QALYs of
0.3754 (95% CI 0.3696–0.3812).
Cost-effectiveness assessment
Economic analysis has shown higher costs in the acu-
puncture group compared to the control group. On the
other hand, acupuncture is more effective. This result has
proven to be robust in bootstrap analyses (Fig. 3; the ma-
jority of 1000 bootstrapped results are located in the upper
right-hand quadrant). The mean ICER was calculated as
relation of cost- and effect-differences between both groups
(Table 3) and was found to be e23,231 per QALY gained
(including overall costs) and e25,315 per additional QALY
(including only asthma-related costs). According to the
most threshold value of e50,000 per QALY gained, acu-
puncture must be considered as a cost-effective treatment
in patients suffering from allergic asthma with a proba-
bility between 86.5% and 88.5% (Fig. 4). Assuming that
society’s willingness to pay would be lower than the as-
sumed e50,000, the probability of cost-effectiveness will
also decrease.
Table 2. Outcomes, Resource Consumption and Costs During the Study Period
Acupuncture (n = 159) Control (n = 147) p-Value
Outcomes used for cost-effectiveness analyses (mean [95% CI])a
Health-state utility 3 months 0.7623 (0.7468–0.7778) 0.7172 (0.7011–0.7334) < 0.001
Health-state utility 6 months 0.7754 (0.7591–0.7918) 0.7320 (0.7156–0.7485) < 0.001
QALYs 0.3754 (0.3696–0.3812) 0.3592 (0.3534–0.3650) < 0.001
Asthma-related quantity of resource consumption (mean number [95% CI])a
Acupuncture sessions 10.81 (10.49–11.13) — < 0.001
Outpatient visits 2.02 (1.16–2.88) 2.16 (1.27–3.06) 0.817
Drug-prescriptions 2.19 (1.89–2.49) 2.04 (1.73–2.35) 0.490
Hospital days — — —
Days of work incapacity 0.09 (0.02–0.17) 0.02 (0.00–0.10) 0.195
Asthma-related costs in euros (mean costs per patient [95% CI])a
Acupuncture 378.40 (367.10–389.69) — < 0.001
Outpatient visits 27.80 (15.29–40.32) 30.03 (17.02–43.05) 0.809
Medication 102.73 (85.53–119.92) 94.10 (76.21–112.00) 0.497
Hospital stays — — —
Indirect costs 5.56 (0.00–20.38) 18.21 (2.78–33.63) 0.248
Total asthma related costs 517.52 (485.63–549.40) 144.87 (111.70–178.05) < 0.001
Total asthma-related costs minus costs of acupuncture 134.22 (105.31–163.13) 144.87 (111.70–178.05) 0.631
Overall quantity of resource consumption (mean number [95%CI])a
Acupuncture sessions 10.81 (10.49–11.13) — < 0.001
Outpatient visits 3.57 (2.47–4.66) 4.90 (3.76–6.04) 0.100
Drug-prescriptions 5.36 (4.73–6.00) 5.33 (4.67–6.00) 0.944
Hospital days 0.28 (0.00–0.60) 0.35 (0.02–0.68) 0.763
Days of work incapacity 1.32 (0.56–2.09) 1.24 (0.45–2.04) 0.886
Overall costs in euros (mean costs per patient [95%CI])a
Acupuncture 378.40 (367.10–389.69) — < 0.001
Outpatient visits 49.29 (33.50–65.08) 67.32 (50.89–83.75) 0.122
Medication 186.69 (157.32–216.06) 166.26 (135.69–196.83) 0.346
Hospital stays 85.26 (0.00–191.389) 104.94 (0.00–215.43) 0.802
Indirect costs 161.07 (80.20–241.94) 179.31 (95.16–263.45) 0.760
Total overall costs 860.76 (705.04–1,016.47) 518.80 (356.66–680.93) 0.003
Total overall costs minus costs of acupuncture 477.17 (321.35–633.00) 518.80 (356.66–680.93) 0.718
aAdjusted for: age, gender, education, duration of disease, number of comorbidities, AQLQ score at baseline, health-state utility at baseline,
respective baseline value.
CI, confidence interval; QALY, quality-adjusted life year.
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FIG. 2. Course of health-
state utilities during the
study. *Real health-state util-
ity of control patients; #mod-
eled new health-state utility
of control patients (assump-
tion: did not receive acu-
puncture during months 3
and 6). QALY, quality-ad-
justed life year.
FIG. 3. Bootstrapped results
on differences in costs and
effects between the treatment
groups.
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As a result of decreasing reimbursement rates for acu-
puncture sessions during the last years in Germany, the
ICER was additionally calculated using 2012 acupuncture
prices of e21 per session (base case: e35 per session).
The mean ICER would decrease to e12,810 (including
overall costs) and e14,911 (including asthma-related costs)
for realizing one additional QALY, showing an increased
cost-effectiveness. Assuming a threshold value of e50,000,
the probability of cost-effectiveness would improve to
values ranging from 91.4% to 94.2%.
Discussion
Acupuncture in addition to routine care compared with
routine care alone was associated with better quality of life as
well as higher costs. This increase of costs was essentially
due to acupuncture costs and was not compensated for by
relevant savings in other health care components during the
study period. The ICER lay between e23,231 (overall) and
e25,315 (diagnosis-specific) per QALY gained. When adopt-
ing a threshold of e50,000 per additional QALY, acupuncture
in addition to routine care is cost-effective.
The present study includes, to the authors’ knowledge, the
first calculation of cost-effectiveness for acupuncture treat-
ment in patients with allergic bronchial asthma. The under-
lying large sample size allows a robust estimation of costs
and effects and is an important basis for a comprehensive
economic assessment. A further strength is the randomized
setting embedded in regular health care that allows drawing
conclusions from the study to everyday treatment.
Nevertheless, some potential limitations should be kept in
mind when interpreting the results of this investigation. A
first limitation results from the fact that the only source of
information for resource consumption and costs consisted of
the statutory health insurance companies’ databases. Thus,
private expenses such as over-the-counter medication or
add-on therapies not reimbursed by the statutory health in-
surance system could not be included.
Another discussion point arises from the design and du-
ration of the study. The cost and effectiveness data were
directly comparable between the two groups for the duration
of 3 months after baseline, since subsequently patients in the
FIG. 4. Cost-effectiveness
probability of additional
acupuncture along different
values of society’s willing-
ness to pay.
Table 3. Incremental Cost-Effectiveness Results
Group differences
(mean [95% CI])a p-Value
QALYs 0.0147 (0.0061–0.0234) 0.001
Asthma-related cost
(in euros)
372.64 (326.36–418.93) < 0.001
Overall costs (in euros) 341.96 (115.88–568.04) 0.003
Resulting ICER in euros (base case)
For asthma-related costs
Mean 25,315
Median (IQR)b 24,822 (15,664)
For overall costs
Mean 23,231
Median (IQR)b 23,163 (20,276)
ICER in euros based on 2012 acupuncture prices
For asthma-related costs
Mean 14,911
Median (IQR)b 14,513 (10,337)
For total costs
Mean 12,810
Median (IQR)b 12,750 (15,822)
aAdjusted for: age, gender, education, duration of disease, number
of comorbidities, AQLQ score at baseline, health-state utility at
baseline, respective baseline value.
bMedian (IQR) were obtained based on bootstrapped ICER results.
ICER, incremental cost-effectiveness ratio; IQR, interquartile
range.
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waiting-list control group were also offered acupuncture.
However, although no further acupuncture sessions were
offered to the acupuncture patients after the first 3 months of
the study, further improvements were observed in quality of
life between months 3 and 6. Comparing both groups only
over the first 3 months would lead to an unjustified under-
estimation of acupuncture effects. As is stated in the Methods
section, we decided to extend the comparison over the
complete period of 6 months. Therefore, it was assumed that
control patients would not get acupuncture between months
3 and 6 and that subsequently they would not have experi-
enced an acupuncture-driven improvement in their quality
of life as was observed in reality. However, the problem
arises that it was unknown what proportion of the observed
improvement in quality of life was achieved by acupuncture
itself, and what proportion might have been a consequence
of seasonal effects (e.g., reduction in allergic symptoms se-
verity due to a seasonal reduced pollen concentration). To
handle this difficulty, it was assumed that control patients
would experience at least the same quality-of-life improve-
ment as that observed in the acupuncture group between
months 3 and 6. This assumption is reflected by a new
modeled 6-month utility for control patients, implying that
the utility trend in control patients during the time would
be the same as was observed in the acupuncture patients
(see the Methods section, and Fig. 2).
Furthermore, the study gives a good example for changes
in cost-effectiveness appraisal over the time. The base-case
analyses presented in the study used a reimbursement rate of
e35 per single acupuncture session. It is important to know
that for services regularly reimbursed by statutory health
insurance companies, no market prices exist in Germany.
Reimbursement rates are rather administratively fixed fees
(not necessarily related to the real costs induced by the use of
general practitioners for the procedure) resulting from ne-
gotiations between the German general practitioners’ orga-
nizations and the statutory health insurance companies. In
this fee, costs for needles and other consumables are sup-
posed to be included. For taking into account recent trends in
reimbursement rates, the cost-effectiveness results were up-
dated by conducting a sensitivity analysis with 2012 acu-
puncture costs of e21. Expectedly, the cost-effectiveness of
acupuncture will increase, but such an isolated view on fi-
nancial aspects can also lead to another interpretation. One
might speculate, however, that a reduction in physicians’
payment could perhaps result in lower treatment effects,
maybe due to less motivated doctors or reduced time in-
vested for conducting the acupuncture.
The main result of the present study is in range with a
number of trials investigating the cost-effectiveness of acu-
puncture for different indications. For example, acupuncture
was found to be a cost-effective treatment in patients suf-
fering from musculoskeletal disorders such as low back pain,
neck pain, or in patients suffering from osteoarthritis.23–25
With regard to allergic disorders, acupuncture was, and is
still investigated in patients with allergic rhinitis so far26 and
was also found to be cost-effective in one large German
study (ICER e17,377 per QALY gained).27 Keeping in mind
the possible link between allergic rhinitis and the develop-
ment of allergic asthma,28,29 acupuncture may offer an ad-
ditional therapeutic option for reducing allergic symptoms
and improving patients’ well-being.
Conclusions
In conclusion, this study shows that treating patients who
have allergic bronchial asthma with acupuncture in addition
to routine care resulted in additional costs and better effects
in terms of patients’ quality of life. Acupuncture therefore
seems to be a useful and cost-effective add-on treatment.
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